-
公开(公告)号:US6080851A
公开(公告)日:2000-06-27
申请号:US448446
申请日:1995-07-10
CPC分类号: C12N15/113 , C12N15/1135 , C07K2319/00 , C12N2310/111 , C12N2310/121 , C12N2310/315 , C12N2310/351 , C12N2310/353 , C12N2310/53
摘要: Ribozymes are provided in which the ribozymes have a catalytic sequence, two legs and at least one anchor sequence complementary to the substrate mRNA at a location noncontiguous with the portions of the substrate mRNA complementary to the legs. In certain preferred embodiments, ribozymes capable of cleaving the L6 mRNA or both the L6 and K28 mRNAs are provided. Methods are provided for the treatment of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) patients having the L6 and K28 translocations and, therefore, the L6 mRNA. Additionally, combination treatments comprising components specific for both the K28 and L6 mRNAs are provided. Combination treatments are also provided for those patients which express c-myc in combination with K28 and/or L6 mRNAs. Methods of treatment include, for example, administration of ribozymes and antisense oligonucleotides directed against these mRNAs.
摘要翻译: PCT No.PCT / US93 / 11144 Sec。 371日期:1995年7月10日 102(e)日期1995年7月10日PCT提交1993年11月16日PCT公布。 出版物WO94 / 13793 日期1994年6月23日提供了这样的酶,其中核酶具有催化序列,两条腿和与底物mRNA互补的位置与底物mRNA互补的至少一个锚定序列。 在某些优选实施方案中,提供能够切割L6 mRNA或L6和K28 mRNA两者的核酶。 提供了用于治疗慢性骨髓性白血病(CML)和具有L6和K28易位的急性淋巴细胞性白血病(ALL)患者以及L6mRNA的方法。 另外,提供包含对K28和L6 mRNA特异性成分的组合处理。 还为那些表达c-myc与K28和/或L6mRNA组合的患者提供组合治疗。 治疗方法包括例如施用针对这些mRNA的核酶和反义寡核苷酸。
-
公开(公告)号:US06831169B2
公开(公告)日:2004-12-14
申请号:US09788934
申请日:2001-05-01
IPC分类号: C12H1511
CPC分类号: C07K14/005 , A61K39/00 , A61K2039/51 , C07K2319/00 , C12N2730/10122 , C12N2770/24222 , C12N2770/24234
摘要: Nucleic acid molecule that comprise an incomplete hepatitis C viral genome are provided. Pharmaceutical compositions that contain nucleic acid molecules comprising an incomplete hepatitis C viral genome including a nucleotide sequence encoding a complete hepatitis C core protein operably linked to regulatory elements functional in human cells are provided. Methods of immunizing individuals susceptible to or infected by hepatitis C virus comprising the step of administering such pharmaceutical compositions are provided.
摘要翻译: 提供了包含不完全丙型肝炎病毒基因组的核酸分子。 提供了含有包含不完全丙型肝炎病毒基因组的核酸分子的药物组合物,其包括编码与人细胞中功能调节元件可操作地连接的完整丙型肝炎核心蛋白的核苷酸序列。 提供了对丙型肝炎病毒敏感或感染的个体进行免疫的方法,包括施用该药物组合物的步骤。
-
公开(公告)号:US06235888B1
公开(公告)日:2001-05-22
申请号:US08869380
申请日:1997-06-05
IPC分类号: C07H2104
CPC分类号: C07K14/005 , A61K39/00 , A61K2039/51 , C07K2319/00 , C12N2730/10122 , C12N2770/24222 , C12N2770/24234
摘要: Nucleic acid molecule that comprise an incomplete hepatitis C viral genome including specifically disclosed DNA sequences are disclosed. Pharmaceutical compositions that contain nucleic acid molecules comprising an incomplete hepatitis C viral genome including a nucleotide sequence encoding a complete hepatitis C core protein operably linked to regulatory elements functional in human cells are disclosed. Methods of immunizing individuals susceptible to or infected by hepatitis C virus comprising the step of administering such pharmaceutical compositions are disclosed.
摘要翻译: 公开了包含特异性公开的DNA序列的包含不完全丙型肝炎病毒基因组的核酸分子。 公开了含有包含不完全丙型肝炎病毒基因组的核酸分子的药物组合物,其包括编码与人细胞中有功能的调控元件可操作地连接的完整丙型肝炎核心蛋白的核苷酸序列。 公开了对丙型肝炎病毒感染或感染的个体进行免疫的方法,包括施用该药物组合物的步骤。
-
-